Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases

NCT01042691 is registered in ClinicalTrials.gov with David Bartlett as lead sponsor.

NCT NCT01042691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01042691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Lead sponsor
David Bartlett
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2003
Completion date
November 30, 2011
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable colorectal liver metastases